Recent insights into astrocytes as therapeutic targets for demyelinating diseases

Curr Opin Pharmacol. 2022 Aug:65:102261. doi: 10.1016/j.coph.2022.102261. Epub 2022 Jul 6.

Abstract

Astrocytes are a group of glial cells that exhibit great morphological, transcriptional and functional diversity both in the resting brain and in response to injury. In recent years, astrocytes have attracted increasing interest as therapeutic targets for demyelinating diseases. Following a demyelinating insult, astrocytes can adopt a wide spectrum of reactive states, which can exacerbate damage, but may also facilitate oligodendrocyte progenitor cell differentiation and myelin regeneration. In this review, we provide an overview of recent literature on astrocyte-oligodendrocyte interactions in the context of demyelinating diseases. We highlight novel key roles for astrocytes both during demyelination and remyelination with a focus on potential therapeutic strategies to favor a pro-regenerative astrocyte response in (progressive) multiple sclerosis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Astrocytes
  • Demyelinating Diseases* / drug therapy
  • Humans
  • Myelin Sheath / physiology
  • Oligodendroglia / physiology
  • Remyelination* / physiology